Shukra Pharmaceuticals Limited has announced outstanding financial results for the third quarter and nine months ended December 31, 2025, showcasing remarkable growth across key performance metrics. The pharmaceutical company's Board of Directors approved these unaudited results during their meeting held on February 4, 2026, pursuant to Regulation 30 and 33 of SEBI Listing Regulations.

Exceptional Quarterly Performance with Strong EBITDA Growth

The company delivered stellar results for Q3FY26, with significant improvements across all major financial parameters. Revenue from operations witnessed substantial growth, while profitability metrics showed exceptional enhancement compared to the previous year. The EBITDA performance was particularly noteworthy, demonstrating the company's operational efficiency.

Strong Nine-Month Performance

The nine-month period ended December 31, 2025, demonstrated consistent growth momentum with impressive year-on-year improvements. The company maintained its growth trajectory across revenue and profitability metrics.

Operational Efficiency and Cost Management

The company demonstrated effective cost management during the quarter. Total expenses for Q3FY26 stood at ₹131.19 crores compared to ₹74.96 crores in Q3FY25. Key expense components included cost of materials consumed at ₹32.00 crores, employee benefit expenses of ₹26.47 crores, and other expenses totaling ₹22.17 crores.

For the nine-month period, total expenses reached ₹256.36 crores against ₹162.93 crores in the corresponding period last year, reflecting the company's expanded operations and business growth.

Board Meeting and Regulatory Compliance

The Board meeting commenced at 3:30 PM and concluded at 4:00 PM on February 4, 2026, at the company's registered office. The directors reviewed the company's business operations and approved the quarterly results in accordance with SEBI regulations. The statutory auditors Shah Sanghvi & Associates provided an unqualified opinion on the financial results.

Regulatory Publication Requirements

Pursuant to Regulation 47 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015, the company published its unaudited financial results in designated newspapers on February 5, 2026. The results were published in Business Standard (English) and Jai Hind (Gujarati) newspapers to ensure compliance with regulatory requirements and provide transparency to stakeholders.

Leadership Continuity

The Board approved the re-appointment of Mr. Dakshesh Shah as Managing Director for a five-year term from December 30, 2025, to December 30, 2030. Mr. Shah brings over 30 years of extensive experience across pharmaceuticals, infrastructure, finance, hospitality, healthcare, and entertainment sectors.

Shukra Pharmaceuticals Limited has completed the allotment of 46,43,000 convertible equity warrants to promoter entities on a preferential basis, as announced following the Board of Directors meeting held on January 28, 2026. The allotment was conducted at an issue price of ₹34 per warrant, with the company receiving an upfront payment of ₹3,94,65,500 representing 25% of the total consideration.

Warrant Allotment Details

The Board approved the allotment to five promoter entities under the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018. The allotment follows the special resolution passed by shareholders at the extraordinary general meeting held on November 01, 2025, and the in-principle approval granted by BSE Limited on January 9, 2026.

Conversion Terms and Timeline

Each warrant is convertible into one fully paid-up equity share with a face value of ₹1 each. The warrant holders must pay the balance consideration of ₹34 per warrant, aggregating to ₹11,83,96,500, representing 75% of the total consideration upon exercise of the conversion option. The warrants carry an 18-month conversion period from the allotment date, allowing holders to exercise conversion in one or more tranches.

The total potential fundraising from this preferential issue amounts to ₹15,78,62,000 upon full conversion of all warrants. Currently, the allotment does not change the company's paid-up share capital, as the warrants represent conversion rights rather than immediate equity shares.

Impact on Shareholding Pattern

The conversion of warrants will result in changes to the promoter shareholding pattern. Post-conversion, the collective promoter holding will increase from 21,77,35,600 shares (49.73%) to 22,23,78,600 shares (50.26%). Anar Project Private Limited will maintain the largest individual holding at 18.86% post-conversion, followed by Parshva Texchem India Private Limited at 17.27%.

Regulatory Compliance

The warrant allotment complies with SEBI ICDR Regulations and follows the preferential allotment framework under the Companies Act, 2013. The Board meeting commenced at 7.10 p.m. and concluded at 7.50 p.m. on January 28, 2026. Any unexercised warrants beyond the 18-month period will lapse, and the amounts paid by warrant holders will be forfeited by the company.